Page last updated: 2024-12-09

Thiophene-2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID1740847
CHEMBL ID2098043
CHEBI ID188588

Synonyms (25)

Synonym
TP2 ,
AK-968/11845359
methyl 2-[(2,3,4,5,6-pentafluorobenzoyl)amino]-5,6,7,8-tetrahydro-4h-cyclohepta[b]thiophene-3-carboxylate
methyl 2-{[(pentafluorophenyl)carbonyl]amino}-5,6,7,8-tetrahydro-4h-cyclohepta[b]thiophene-3-carboxylate
STK421517
thiophene-2
methyl 2-[(2,3,4,5,6-pentaluorobenzoyl)amino]-5,6,7,8-tetrahydro-4h-cyclohepta[b]thiophene-3-carboxylate
CHEBI:188588
AKOS003236707
tcmdc-142439
gsk140123a
CHEMBL2098043
methyl 2-(perfluorobenzamido)-5,6,7,8-tetrahydro-4h-cyclohepta[b]thiophene-3-carboxylate
4h-cyclohepta[b]thiophene-3-carboxylic acid, 5,6,7,8-tetrahydro-2-[(pentafluorobenzoyl)amino]-, methyl ester
thiophene-2, >=98% (hplc)
mmv461553
5,6,7,8-tetrahydro-2-[(2,3,4,5,6-pentafluorobenzoyl)amino]-4h-cyclohepta[b]thiophene-3-carboxylic acid methyl ester
420089-51-6
HY-117145
CS-0063999
BB 0323222
sr-05000022525
SR-05000022525-1
PD013393
DTXSID401346310
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organosulfur heterocyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1489696Antitubercular activity against Mycobacterium tuberculosis by microdilution method2018Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis.
AID1593397Antitubercular activity against Mycobacterium tuberculosis H37Rv by microdilution method2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
AID1571161Antitrypanosomal activity against Trypanosoma brucei brucei 427 bloodstream forms assessed as parasite viability at 10 uM after 24 hrs by resazurin dye based fluorescence assay relative to control2018MedChemComm, Dec-01, Volume: 9, Issue:12
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.
AID1571159Antitrypanosomal activity against Trypanosoma brucei brucei 427 bloodstream forms after 48 hrs by resazurin dye based fluorescence assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.
AID1571162Antitrypanosomal activity against Trypanosoma brucei brucei 427 bloodstream forms after 24 hrs by resazurin dye based fluorescence assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.
AID1736312Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth2020European journal of medicinal chemistry, Mar-01, Volume: 189Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis.
AID1852583Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth incubated for 7 days by MABA
AID1571164Selectivity index, ratio of IC50 for human HeLa cells to IC50 for Trypanosoma brucei brucei 427 bloodstream forms2018MedChemComm, Dec-01, Volume: 9, Issue:12
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.
AID1571163Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin dye based fluorescence assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.
AID1288655Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by microdilution method
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]